Project Details
| Status | Active |
|---|---|
| Effective start/end date | 10/25/19 → 8/31/50 |
Funding
- MedImmune, Inc.
A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY)
- Muller, William J (PD/PI)
Project: Research project